People: Research Team

Dr. Giulia Biffi, co-lead

Giulia Biffi is a Group Leader at the Cancer Research UK Cambridge Institute, University of Cambridge. Her laboratory works to understand the biology of pancreatic cancer, with aim of identifying more effective treatments for patients.

Read More
Professor Duncan Jodrell, DM MSc FRCP(Edin.) – Researcher and Medical Oncologist 

Duncan is the Professor of Cancer Therapeutics at the University of Cambridge. He is the Cambridge Experimental Cancer Medicine Centre (ECMC) Lead, Director of the Cambridge Cancer Trials Centre (CCTC) and an honorary consultant at Addenbrooke’s Hospital.

Read More
Professor Ashok Venkitaraman; Director of the Cancer Science Institute of Singapore; Distinguished Professor of Medicine, Yong Loo Lin School of Medicine, National University of Singapore (NUS); Director, NUS Center for Cancer Research; Programme Director, A*STAR, Singapore

Ashok Venkitaraman, formerly the Ursula Zoellner Professor of Cancer Research at the University of Cambridge from 1998-2020 and Director of the MRC Cancer Cell Unit from 2006-19, relocated in 2020 to new roles in Singapore.  He is now a Distinguished Professor of Medicine at the National University of Singapore (NUS), and directs the Cancer Science Institute of Singapore, a Research Centre of Excellence hosted by NUS. Ashok leads the NUS Centre for Cancer Research, and is a Programme Director at A*STAR in Singapore. Ashok previously co-led the Cambridge Pancreatic Cancer Programme with Duncan Jodrell.

Read More
Dr. Martin L Miller MSc PhD

Martin is a Group Leader at the Cancer Research UK Cambridge Institute. His research is focused on cell-cell interactions in the tumour microenvironment and unravelling stroma-mediated drug resistance in human cancers using proteomic technologies.

Read More
Dr. Tim Halim

Tim is a Group Leader at the Cancer Research UK – Cambridge Institute, University of Cambridge. He obtained his PhD in 2013 at the University of British Columbia (Canada), after which he moved to the laboratory of Dr. Andrew McKenzie at the MRC Laboratory of Molecular Biology (UK) on a CIHR Banting Fellowship.

Read More
Professor Jason Carroll

Jason Carroll is a Professor of Molecular Oncology at the University of Cambridge, a Senior Group Leader at Cancer Research UK, a Fellow at Clare College and was elected an EMBO member in 2016 and a Fellow of the Academy of Medical Sciences in 2017. His lab is interested in understanding mechanisms of hormone-dependent cancer.

Read More
Dr. Trevor Littlewood – Research scientist

Trevor co-runs (with Professor Gerard Evan) an academic research group at the University of Cambridge, department of biochemistry. Trevor’s interest in oncogenic signalling started at the Ludwig Institute for Cancer Research in the late 1980s and continued at the Imperial Cancer Research Fund (now CR UK), the MRC laboratory of Medical Biology and, since 2010, at the department of biochemistry.

Read More
Professor George Malliaras

George Malliaras is the Prince Philip Professor of Technology at the University of Cambridge. He is leading the EPSRC IRC on Targeted Delivery for Hard-to-Treat Cancers and works on electrophoretic drug delivery devices.

Read More
Dr. Michael (Mike) Gill

Mike is a Principal Scientific Associate in the Miller lab at the Cancer Research UK- Cambridge Institute, University of Cambridge. He obtained his Ph.D. in 2000 at the University of Cambridge, after which he moved to the laboratory of Dr Joyce Fingeroth at Harvard University, and then returned to the University of Cambridge in 2005 to take a position in the Division of Virology, Department of Pathology.

Read More
Gerard Evan, Ph.D. Sir William Dunn Professor of Biochemistry

Gerard runs a research group focused on the elucidation of oncogene-mediated stromal changes and immune suppression in cancer and is the Sir William Dunn Professor and Head of the Department of Biochemistry.

Read More
Professor Kevin Brindle

Kevin is a senior group leader at the CRUK Cambridge Institute where his lab works in the field of molecular imaging.  The primary focus of their work is early detection of tumour treatment response with the aim of developing imaging methods that could be used in early phase clinical trials to get an indication of drug efficacy, and subsequently in the clinic to guide treatment in individual patients.

Read More